Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved leniolisib (Joenja) for children aged 4–11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare genetic immune disorder. Previously approved only for patients 12 and older, the drug now offers the first targeted treatment for younger kids using a weight-based dosing approach. Experts call it a "game-changer," but warn that a decade-long average diagnostic delay remains a critical barrier.
The FDA has expanded approval of leniolisib (Joenja) to include children aged 4–11 years weighing at least 27 kg, making it the first targeted treatment for this age group with activated phosphoinositide 3-kinase delta syndrome (APDS). Originally approved in 2023 for patients 12 and older, the drug directly targets the dysfunctional PIK3CD or PIK3R1 gene mutations that impair immune cells, leaving patients vulnerable to recurrent infections of the respiratory tract, sinuses, and ears.
The expanded approval was based on an open-label study of eight younger patients, with weight-based dosing of 40, 50, or 70 mg twice daily. Experts emphasize that since APDS symptoms typically emerge around age 2 and damage accumulates over time, earlier treatment could be transformative — but only if children are diagnosed promptly.
Key Takeaways:
Why it matters: With a targeted therapy now available for young children, the historically long diagnostic delay is no longer just a clinical frustration — it represents years of preventable disease progression. Broader genetic testing access and clinician awareness are urgently needed.
